Business
Rigel Announces Second REZLIDHIA® (Olutasidenib) Publication in Blood Advances
Review article examines the preclinical and clinical development, and the role of olutasidenib in the mIDH1 AML treatment landscape.Authors conclude, "The
About this update from Rigel Pharmaceuticals, Inc.
[{"type":"text","content":"Review article examines the preclinical and clinical development, and the role of olutasidenib in the mIDH1 AML treatment landscape.Authors conclude, \"The approval of olutasidenib is a critical addition to the mIDH1 AML treatment landscape with encouragingly durable responses.\"SOUTH SAN FRANCISCO, Calif., June 6, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced an expert review article in Blood Advances examining the development path and positioning of REZLIDHIA® (olutasidenib), a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase-1 (mIDH1)1, in the mIDH1 relapsed/refractory (R/R) acute myeloid leukemia (AML) treatment landscape. \n\"The compelling safety and efficacy results observed in REZLIDHIA trials to date, marked by encouragingly durable responses, represent an important advance for mIDH1 R/R AML patients and treating physicians,\" said Justin Watts, M.D., Lead Author and Associate Professor of Medicine, Division of Hematology, Chief, Leukemia Section at the University of Miami Health System. \"These data are particularly supportive of the use of REZLIDHIA in mIDH1 R/R AML patients who have failed intensive chemotherapy or venetoclax plus HMA combination therapy. The results validate ongoing studies evaluating olutasidenib in frontline and R/R settings as a monotherapy and in combination with azacitidine with or without prior exposure to HMA or IDH1 inhibitor.\" \n\"We are pleased with the growing body of evidence and thought leader support for REZLIDHIA as a differentiated and potentially market-leading therapy for mIDH1 R/R AML patients,\" said Raul Rodriguez, Rigel's president and CEO. \"We remain committed to delivering this important treatment option to mIDH1 R/R AML patients and look forward to data from the ongoing studies of REZLIDHIA in broader mIDH1 AML treatment settings.\"\nKey points from the paper are summarized below:\nREZLIDHIA demonstrated highly durable remission rates, representing a critical addition to the mIDH1 AML treatment landscapeThe available data support the use of REZLIDHIA as monotherapy in R/R AML patients who have failed intensive chemotherapy or venetoclax plus HMA combination therapyThe authors state that the choice of which IDH1 inhibitor to use first in these patients is not yet clear, although given the available data R...